Related Experiment Video
Updated: May 16, 2026
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
Development of antibody therapeutics for small cell lung cancer
Jinbiao Zhan1, Qi Han, Keyi Wang
1Zhejiang University School of Medicine, Department of Biochemistry, Laboratory for Gene and Antibody Engineering, Hangzhou 310058, PR China. jzhan2k@zju.edu.cn
Introduction:
Small cell lung cancer (SCLC) is one of most aggressive cancers and only modest improvements have been achieved in overall survival over last 30 years. In recent years, antibody therapeutics has been actively studied and shown promise in treatment of SCLC.
Areas Covered:
A comprehensive literature search through Medline and the registry database of clinical trials (ClinicalTrials.gov) was performed to collect all relevant preclinical and clinical data. The diverse antibody therapeutics which target against different antigens including VEGE-A, CEA, IGF-1R, CD56, EpCAM, CTLA-4, gangliosides GD2 and GD3, Lewis Y and tenascin-C are now under clinical investigation for therapeutic effects in SCLC.
Expert Opinion:
During the last few decades, progresses have been made in antibody therapy for SCLC, however great challenges still remain. The major reasons are the complexity of SCLC and a lack of understanding of cancer immunology. The profound studies of signaling pathways involved in carcinogenesis, proliferation, metastasis and apoptosis in SCLC are crucial for the identification of new therapeutic targets and biomarkers. Moreover, a better understanding of the interplay between cancer and the immune system is a new direction for the design of more effective antibody therapeutics.
Insights
Antibody therapeutics show promise for treating small cell lung cancer (SCLC), an aggressive disease with limited survival improvements. Further research into SCLC complexity and cancer immunology is crucial for developing more effective treatments.
Area of Science:
- Oncology
- Immunotherapy
- Drug Development
Background:
- Small cell lung cancer (SCLC) is a highly aggressive malignancy with historically poor patient survival rates.
- Despite decades of research, significant improvements in overall survival for SCLC patients remain elusive.
- Antibody therapeutics represent a promising avenue for SCLC treatment, with ongoing clinical investigations.
Purpose of the Study:
- To review the current landscape of antibody therapeutics investigated for SCLC treatment.
- To identify key challenges and future directions in the development of antibody-based therapies for SCLC.
Main Methods:
- A comprehensive literature search was conducted using Medline and ClinicalTrials.gov.
- Preclinical and clinical data on antibody therapeutics targeting various antigens in SCLC were collected and analyzed.
Main Results:
- Multiple antibody therapeutics targeting antigens such as VEGFA, CEA, IGF-1R, CD56, EpCAM, CTLA-4, GD2, GD3, Lewis Y, and tenascin-C are under clinical investigation.
- Progress has been made in antibody therapy for SCLC, but significant challenges persist.
Conclusions:
- The complexity of SCLC and incomplete understanding of cancer immunology are major hurdles.
- Further research into SCLC signaling pathways is essential for identifying new therapeutic targets and biomarkers.
- A deeper understanding of cancer-immune system interactions is vital for designing next-generation antibody therapeutics.
More Related Videos
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
08:53In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
Published on: September 16, 2019
